PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.78), $0.24 worse than the analyst estimate of ($1.54). Revenue for the quarter came in at $148.73 million versus the consensus estimate of $146.9 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.